De novo acute myeloid leukemia: A population‐ based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)

(2020) Gautam M. Borthakur et al.   BLOOD

Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study

(2020) Sabine Kayser et al.   LEUKEMIA

Venetoclax in acute myeloid leukemia – current and future directions

(2020) Curtis Lachowiez et al.   LEUKEMIA & LYMPHOMA

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

(2020) Nicholas J. Short et al.   Cancer Discovery

Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial

(2020) Andrew Henry Wei et al.   BLOOD

Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis

(2020) Kelly J. Norsworthy et al.   LEUKEMIA

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

(2020) Courtney D DiNardo et al.   Lancet Haematology

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

(2020) Andrew H. Wei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting FLT3 mutations in AML: review of current knowledge and evidence

(2019) Naval Daver et al.   LEUKEMIA

Venetoclax-based Therapies for Acute Myeloid Leukemia

(2019) Veronica A. Guerra et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

(2019) Mark J. Levis et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of Baseline FLT3 ‐ITD Mutant Allele Level in Acute Myeloid Leukemia Treated with Intensive Chemotherapy With/Without Sorafenib

(2019) Fevzi Yalniz et al.   AMERICAN JOURNAL OF HEMATOLOGY

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia

(2019) Koji Sasaki et al.   CANCER

Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014: improving performance status is a major contributing factor

(2019) Åsa Derolf et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3 -ITD Mutated Acute Myeloid Leukemia (AML)

(2018) Maro Ohanian et al.   AMERICAN JOURNAL OF HEMATOLOGY

Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California

(2018) Gwendolyn Ho et al.   CANCER

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

(2018) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations

(2018) Michael Buege et al.   Cancers

Acute myeloid leukaemia

(2018) Nicholas J Short et al.   LANCET

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

(2018) Tapan M Kadia et al.   Lancet Haematology

Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

(2018) Richard F. Schlenk et al.   BLOOD

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML

(2018) Courtney D. DiNardo et al.   Clinical Lymphoma Myeloma & Leukemia

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

(2018) Jorge E. Cortes et al.   LEUKEMIA

Influence of IDH on FLT3-ITD status in newly diagnosed AML

(2017) P Boddu et al.   LEUKEMIA

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

(2017) Brittany Knick Ragon et al.   Current Hematologic Malignancy Reports

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

(2016) Yasmin Abaza et al.   BLOOD

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2016) John S. Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute myeloid leukemia-Major progress over four decades and glimpses into the future

(2015) Hagop Kantarjian   AMERICAN JOURNAL OF HEMATOLOGY

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

(2015) Tapan M. Kadia et al.   CANCER

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

(2015) Christoph Röllig et al.   LANCET ONCOLOGY

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toward Individualized Therapy in Acute Myeloid Leukemia

(2015) Tapan M. Kadia et al.   JAMA Oncology

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

(2014) Gautam Borthakur et al.   AMERICAN JOURNAL OF HEMATOLOGY

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

(2014) Jean-Pierre Issa et al.   CANCER

High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

(2013) Roelof Willemze et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytarabine Dose for Acute Myeloid Leukemia

(2011) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals

(2008) Simone Mathoulin-Pelissier et al.   JOURNAL OF CLINICAL ONCOLOGY

Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

(2008) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY